We also found high OTUD6B expression to correlate with significantly reduced progression‐free survival in patients treated with the proteasome inhibitor bortezomib, which is approved for all treatment lines of MM (Fig 6F; Mulligan et al, 2007; Kumar et al, 2017; Manasanch & Orlowski, 2017). The gene discussed is OTUD6B; the disease is Miyoshi myopathy.